Joerg Zeller

This inventor holds 21 USPTO granted patents and 19 published patent applications, plus 4 CIPO patents and 7 EPO patents, primarily in Antagonist Antibodies. Top assignees: Labrys Biologics, Inc., Teva Pharmaceuticals International Gmbh, Pfizer Corporation. Active years: 2011-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joerg Zeller. Retrieved from https://idiyas.com/inventor/joerg-zeller

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 19)

% Patents Active = 95.2

CIPO Patents = 4

EPO Patents = 7 (Patent Applications = 6)

Average Co-Inventor Count = 5.5

ph-index = 15

Forward Citations = 524(Granted Patents)

Location History:

San Francisco, CA (US) (2012)
North Wales, PA (US) (2019)
Ann Arbor, MI (US) (2011 - 2020)

Company Filing History:

11 out of 11

Labrys Biologics, Inc.

patents

7 out of 54

Teva Pharmaceuticals International Gmbh

Rinat Neuroscience Corporation

patents

Years Active: 2011-2020

Loading Chart...

Areas of Expertise:

Antagonist Antibodies

Calcitonin Gene-Related Peptide

Visceral Pain

Chronic Pain

Fibromyalgia

Headache Treatment

CGRP Antagonists

Inflammatory Pain

Vasomotor Symptoms

Pain Management

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10597448 - Methods for treating visceral pain associated with interstitial cystitis by administering antagonist antibodies directed against calcitonin gene-related peptide (2020-03-24),

2. 10329343 - Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide (2019-06-25),

3. 10323085 - Methods of treating fibromyalgia (2019-06-18),

4. 9890211 - Antagonist antibodies directed against calcitonin gene-related peptide (2018-02-13),

5. 9890210 - Antagonist antibodies directed against calcitonin gene-related peptide (2018-02-13),

6. 9884908 - Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide (2018-02-06),

7. 9884907 - Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide (2018-02-06),

8. 9365648 - Methods of using anti-CGRP antagonist antibodies (2016-06-14),

9. 9346881 - Antagonist antibodies directed against calcitonin gene-related peptide and methods using same (2016-05-24),

10. 9340614 - Antagonist antibodies directed against calcitonin gene-related peptide and methods using same (2016-05-17),

11. 9328168 - Methods of using anti-CGRP antagonist antibodies (2016-05-03),

12. 9328167 - Methods of treating chronic pain (2016-05-03),

13. 9266951 - Antagonist antibodies directed against calcitonin gene-related peptide and methods using same (2016-02-23),

14. 9115194 - Antagonist antibodies directed against calcitonin gene-related peptide and methods using same (2015-08-25),

15. 8734802 - Methods of treating vasomotor symptoms using antibodies (2014-05-27),

Title: The Innovative Journey of Joerg Zeller

Introduction: Joerg Zeller, a talented inventor based in Ann Arbor, MI, has made significant contributions to the field of technology with his creative solutions and groundbreaking ideas.

Latest Patents: Joerg Zeller's latest patents focus on advancements in renewable energy technologies, particularly in the development of solar-powered devices for sustainable living.

Career Highlights: With a background in engineering and a passion for innovation, Joerg Zeller has successfully brought several inventions from concept to market, showcasing his expertise in product development and design.

Collaborations: Throughout his career, Joerg Zeller has collaborated with leading research institutions and tech companies to further enhance his inventions and bring cutting-edge solutions to the market.

Conclusion: Joerg Zeller's dedication to innovation and his commitment to creating a more sustainable future through his inventions make him a standout figure in the world of technology.

Profile summary based on public USPTO records.